Relapse – Talk Bio

Kyverna’s CAR-T Relapse in Lupus Dents Autoimmune Hopes Amid Biotech Gold Rush

12 months ago talkbio0Tagged Autoimmune Diseases, biotech, CAR-T, Clinical Trials, gene therapy, Kyverna, Lupus Vulgaris, Relapse

Kyverna, CAR-T, Lupus, Autoimmune Disease, Biotech, Gold Rush, Relapse, Clinical Trials, Gene Therapy

Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis

1 year ago talkbio0Tagged Clinical, Lesion, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple Sclerosis, Ocrevus, Relapse, Roche (company)

Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures

AstraZeneca’s Ultomiris Gains FDA Approval for Rare Autoimmune Condition – NMOSD

1 year ago talkbio0Tagged Approved, AstraZeneca, Autoimmune Diseases, dosing, Infrequent, Long-acting C5 complement inhibitor, Neuromyelitis Optica, Rating (action), ravulizumab-cwvz, Reduced, Relapse, Ultomiris, United States Food and Drug Administration, With frequency

AstraZeneca, Ultomiris, ravulizumab-cwvz, FDA Approval, Rare Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), Long-acting C5 complement inhibitor, Phase 3 CHAMPION-NMOSD Trial, Reduced Relapse Rate, Dosing Frequency